{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T19:03:13Z","timestamp":1762023793808,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 026877"],"award-info":[{"award-number":["P30 026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.survophthal.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T02:10:23Z","timestamp":1591927823000},"page":"543-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A tearfully painful darkness"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-4937","authenticated-orcid":false,"given":"Lakshmi","family":"Leishangthem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Beres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7528","authenticated-orcid":false,"given":"John","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.msard.2020.101965","article-title":"Prodromal headache in MOG-antibody positive optic neuritis","volume":"40","author":"Asseyer","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.survophthal.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.survophthal.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1212\/NXI.0000000000000543","article-title":"Cranial nerve involvement in patients with MOG antibody-associated disease","volume":"6","author":"Cobo-Calvo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"21","key":"10.1016\/j.survophthal.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.survophthal.2020.06.002_bib7","first-page":"806","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.survophthal.2020.06.002_bib8","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.survophthal.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11926-018-0737-1","article-title":"Recent advances in giant cell arteritis","volume":"20","author":"Guevara","year":"2018","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.survophthal.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"10.1016\/j.survophthal.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"12","key":"10.1016\/j.survophthal.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.survophthal.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis optica spectrum disorder and anti-MOG syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.survophthal.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.survophthal.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"Salama","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"22","key":"10.1016\/j.survophthal.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.2169\/internalmedicine.2845-19","article-title":"Aseptic meningitis as an initial manifestation of anti-myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"58","author":"Suzuki","year":"2019","journal-title":"Intern Med"},{"issue":"12","key":"10.1016\/j.survophthal.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11910-019-1014-z","article-title":"Clinical characteristics and treatment of MOG-IgG-associated optic neuritis","volume":"19","author":"Tajfirouz","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011031014433","article-title":"Immune responses against the myelin\/oligodendrocyte glycoprotein in experimental autoimmune demyelination","volume":"21","author":"von Budingen","year":"2001","journal-title":"J\u00a0Clin Immunol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625720300989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625720300989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:51:44Z","timestamp":1758541904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625720300989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0039625720300989"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.06.002","relation":{},"ISSN":["0039-6257"],"issn-type":[{"type":"print","value":"0039-6257"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tearfully painful darkness","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}